Rusthoven Kyle E, Raben David, Ballonoff Ari, Kane Madeleine, Song John I, Chen Changhu
Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado 80045-0508, USA.
Laryngoscope. 2008 Apr;118(4):635-9. doi: 10.1097/MLG.0b013e31815fdf0e.
To compare the toxicity and outcomes of three radiotherapy techniques-three-dimensional conformal (3D-RT), accelerated fractionation with concomitant boost (AFxCB), and intensity modulated radiotherapy (IMRT)-in the combined modality treatment of stage III-IV squamous cell carcinoma (SCC) of the oropharynx.
Retrospective review.
Between 1998 and 2007, a total of 87 patients were treated; 23 were treated with 3D-RT, 32 with AFxCB, and 32 with IMRT. Systemic therapy consisted of platinum-based chemotherapy in 81 and anti-epidermal growth factor receptor (anti-EGFR)-targeted therapy in 6 cases. Median radiotherapy doses were 70Gy with 3D-RT, 72Gy with AFxCB, and 69.3Gy with IMRT. Locoregional control, survival outcomes, and feeding tube (PEG) dependence were compared using log-rank method. The incidence of acute mucositis and skin reaction, and grade > or = 2 xerostomia at 6, 12, and 18 months after radiotherapy was compared using Fisher's exact test.
Median follow-up was 24 months (range 3 to 103 months) for living patients. Two-year overall survival (OS), disease-free survival (DFS), and locoregional control (LRC) were 77.3%, 69.5%, and 86.4%, respectively. There was a trend toward improvement in LRC in patients treated with IMRT. Acute grade > or = 3 skin and mucosal toxicity were significantly lower with IMRT compared to AFxCB (P < .001). Grade > or = 2 xerostomia was significantly reduced with IMRT compared to AFxCB and 3D-RT (P < .001). There was no difference in the actuarial rate of PEG dependence (P = .96).
Compared to AFxCB and 3D-RT, IMRT confers an improvement in toxicity and appears to have similar efficacy in patients with SCC of the oropharynx.
比较三维适形放疗(3D-RT)、加速分割同步推量放疗(AFxCB)和调强放疗(IMRT)这三种放疗技术在口咽Ⅲ-Ⅳ期鳞状细胞癌(SCC)综合治疗中的毒性及治疗效果。
回顾性研究。
1998年至2007年间,共治疗87例患者;23例接受3D-RT治疗,32例接受AFxCB治疗,32例接受IMRT治疗。全身治疗包括81例接受铂类化疗,6例接受抗表皮生长因子受体(anti-EGFR)靶向治疗。3D-RT的中位放疗剂量为70Gy,AFxCB为72Gy,IMRT为69.3Gy。采用对数秩检验比较局部区域控制、生存结果和胃造瘘管(PEG)依赖情况。采用Fisher精确检验比较放疗后6、12和18个月时急性黏膜炎和皮肤反应的发生率以及≥2级口干的发生率。
存活患者的中位随访时间为24个月(范围3至103个月)。两年总生存率(OS)、无病生存率(DFS)和局部区域控制率(LRC)分别为77.3%、69.5%和86.4%。接受IMRT治疗的患者LRC有改善趋势。与AFxCB相比,IMRT的急性≥3级皮肤和黏膜毒性显著更低(P<.001)。与AFxCB和3D-RT相比,IMRT的≥2级口干显著减少(P<.001)。PEG依赖的精算发生率无差异(P =.96)。
与AFxCB和3D-RT相比,IMRT可改善毒性,且对口咽SCC患者似乎具有相似的疗效。